Premium
The Combination of Amoxicillin and Metronidazole Improves Clinical and Microbiologic Results of One‐Stage, Full‐Mouth, Ultrasonic Debridement in Aggressive Periodontitis Treatment
Author(s) -
Casarin Renato C.V.,
Peloso Ribeiro Érica Del,
Sallum Enilson A.,
Nociti Francisco H.,
Gonçalves Reginaldo B.,
Casati Márcio Z.
Publication year - 2012
Publication title -
journal of periodontology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.036
H-Index - 156
eISSN - 1943-3670
pISSN - 0022-3492
DOI - 10.1902/jop.2012.110513
Subject(s) - metronidazole , amoxicillin , medicine , tannerella forsythia , aggressive periodontitis , aggregatibacter actinomycetemcomitans , periodontitis , debridement (dental) , dentistry , gastroenterology , chronic periodontitis , placebo , porphyromonas gingivalis , antibiotics , microbiology and biotechnology , pathology , honeysuckle , alternative medicine , traditional chinese medicine , biology
Background: The aim of the present study is to assess clinical, microbiologic, and immunologic benefits of amoxicillin/metronidazole (AM) when performing full‐mouth ultrasonic debridement (FMUD) in generalized aggressive periodontitis (GAgP) treatment. Methods: Twenty‐four GAgP patients were divided into two groups: the FMUD group (n = 12), which received FMUD plus placebo, and the FMUD+AM group (n = 12), which received FMUD and 375 mg amoxicillin plus 250 mg metronidazole for 7 days. The following clinical outcomes were tested: plaque and bleeding on probing indices, pocket probing depth (PD), relative gingival margin position (GMP), and relative clinical attachment level (CAL). Total amount of Porphyromonas gingivalis ( Pg ), Aggregatibacter actinomycetemcomitans ( Aa ), Tannerella forsythia ( Tf ), and gingival crevicular fluid (GCF) concentration of interleukin (IL)‐10 and IL‐1β were also determined. All clinical, microbiologic, and immunologic parameters were assessed at baseline and at 3 and 6 months post‐therapy. The ANOVA/Tukey test was used for statistical analysis (α = 5%). Results: Amoxicillin/metronidazole used as an adjunct to the FMUD protocol added clinical and microbiologic benefits to GAgP treatment ( P <0.05). FMUD+AM groups presented an additional PD reduction in initially deep PDs at the 3‐month follow‐up (3.99 ± 1.16 mm and 3.09 ± 0.78 mm for FMUD+AM and FMUD, respectively; P <0.05), a lower number of residual pockets at the 3‐ and 6‐month follow‐ups, and a statistical reduction in amounts of Aa ( P <0.05). Analysis of Tf and Pg amounts, as well as IL‐10 and IL‐1β GCF concentrations failed to demonstrate a difference between the groups ( P >0.05). Conclusion: It may be concluded that amoxicillin/metronidazole improves clinical and microbiologic results of FMUD in GAgP treatment.